1.Advances on the anti-inflammatory and protective effect of AMPK activators.
Xian-Wen PENG ; Hong-Hong ZHOU ; Jie DAI ; Li ZHANG
Acta Physiologica Sinica 2019;71(2):319-326
AMP-activated protein kinase (AMPK) is a key enzyme in the regulation of cellular energy homeostasis. Recent studies demonstrated that AMPK also plays an important role in the modulation of inflammation, an energy-intensive molecular response. The commonly used AMPK activators include 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and A-769662. In addition, the biological activities of metformin and adiponectin are closely related to activation of AMPK. Numerous studies have shown that these AMPK activators play an effectively protective role in animal models of acute lung injury, asthma, colitis, hepatitis, atherosclerosis and other inflammatory diseases. Therefore, AMPK activators may have promising potential for the prevention and treatment of inflammation related diseases.
AMP-Activated Protein Kinases
;
physiology
;
Adiponectin
;
pharmacology
;
Aminoimidazole Carboxamide
;
pharmacology
;
Animals
;
Enzyme Activation
;
Inflammation
;
enzymology
;
Metformin
;
pharmacology
;
Pyrones
;
pharmacology
;
Thiophenes
;
pharmacology
2.The changes of vascular active substances in pulmonary embolism rats and a comparative study of anticoagulant drugs.
Ying ZHANG ; Wei FENG ; Cun-zi YAN ; Ai-mu-xi-ka-mai-er Ai-he-mai-ti XI ; Yong LIN ; Hui LU
Chinese Journal of Applied Physiology 2015;31(2):178-185
OBJECTIVETo establish the rat model of acute pulmonary embolism, and study the changes of vascular active substances in pulmonary embolism rats, and investigate the interventive effect of anticoagulant drugs on vascular active substances.
METHODSOne hundred and twenty-eight rats were randomly divided into four groups: control group, model group, low-molecular-weight heparin and warfarin treated group and rivaroxaban-treated group (n = 32 in each group). The method of autologous thrombosis was used to establish the animal model of acute pulmonary embolism. The animals were treated with saline or different anticoagulant drugs. The physiological and biochemical parameters were detected at different time points after embolization. The rats were killed after embolism of 24 h, 3 d, 5 d or 1 week respectively and the pathologic samples of lung tissues were collected to analyze the pulmonary pathological changes in different groups.
RESULTSRats in embolization group after blood clots injection showed shortness of breath, oral cyanosis; quicken heart rates and other symptoms. All embolization groups had pulmonary hypertension, the levels of type B natriuretic peptide (BNP) were increased significantly. The ratio of endothelin-1 (ET-1)/NO and thromboxane (TXB2) and prostacyclin (6-k-PGFla) were abnormal. After treated with effective anticoagulant drugs, the levels of BNP, ET-1, NO, TXB2 and 6-k-PGF1a were tended to the normal levels in the control group. The pulmonary hypertensions were gradually decreased. The efficacy of rivaroxaban on pulmonary embolism was the same as that of the low molecular weight heparin or warfarin.
CONCLUSIONAnticoagulation therapy can effectively improve endothelial function after pulmonary embolism, reduce pulmonary hypertension, and revise the increased BNP levels to normal levels. The efficacy of rivaroxaban is not inferior to that of low molecular weight heparin and warfarin.
Animals ; Anticoagulants ; pharmacology ; Disease Models, Animal ; Endothelin-1 ; metabolism ; Heparin, Low-Molecular-Weight ; pharmacology ; Hypertension, Pulmonary ; drug therapy ; metabolism ; Lung ; pathology ; Morpholines ; pharmacology ; Pulmonary Embolism ; drug therapy ; metabolism ; Rats ; Rivaroxaban ; Thiophenes ; pharmacology ; Warfarin ; pharmacology
3.Expression of ubiquitin-specific protease 7 in lung tissue of preterm rats after hyperoxia exposure.
Xiao-Yue HUANG ; Yu-Feng QUAN ; Long-Li YAN ; Lin ZHAO
Chinese Journal of Contemporary Pediatrics 2020;22(12):1331-1337
OBJECTIVE:
To study the expression and significance of ubiquitin-specific protease 7 (USP7) and the key factors of the Wnt signaling pathway in the lung tissue of preterm rats after hyperoxia exposure.
METHODS:
A total of 180 preterm neonatal Wistar rats were randomly divided into an air control group, an air intervention group, a hyperoxia control group, and a hyperoxia intervention group, with 45 rats in each group. Lung injury was induced by hyperoxia exposure in the hyperoxia groups. The preterm rats in the intervention groups were given intraperitoneal injection of the USP7 specific inhibitor P5091 (5 mg/kg) every day. The animals were sacrificed on days 3, 5, and 9 of the experiment to collect lung tissue specimens. Hematoxylin-eosin staining was used to observe the pathological changes of lung tissue. RT-PCR and Western blot were used to measure the mRNA and protein expression levels of USP7 and the key factors of the Wnt signaling pathway β-catenin and α-smooth muscle actin (α-SMA) in lung tissue.
RESULTS:
The air groups had normal morphology and structure of lung tissue; on days 3 and 5, the hyperoxia control group showed obvious alveolar compression and disordered structure, with obvious inflammatory cells, erythrocyte diapedesis, and interstitial edema. On day 9, the hyperoxia control group showed alveolar structural disorder and obvious thickening of the alveolar septa. Compared with the hyperoxia control group at the corresponding time points, the hyperoxia intervention group had significantly alleviated disordered structure, inflammatory cell infiltration, and bleeding in lung tissue. At each time point, the hyperoxia groups had a significantly lower radial alveolar count (RAC) than the corresponding air groups (
CONCLUSIONS
Hyperoxia exposure can activate the Wnt/β-catenin signaling pathway, and USP7 may participate in hyperoxic lung injury through the Wnt/β-catenin signaling pathway. The USP7 specific inhibitor P5091 may accelerate the degradation of β-catenin by enhancing its ubiquitination, reduce lung epithelial-mesenchymal transition, and thus exert a certain protective effect against hyperoxic lung injury.
Animals
;
Animals, Newborn
;
Hyperoxia/physiopathology*
;
Lung/physiopathology*
;
Random Allocation
;
Rats
;
Rats, Wistar
;
Thiophenes/pharmacology*
;
Ubiquitin-Specific Peptidase 7/metabolism*
;
Ubiquitin-Specific Proteases
;
Wnt Signaling Pathway
4.Mechanism and action characteristics studies of a quinoxalinone compound against HIV-1 replication.
Ming-Yu BA ; Ying-Li CAO ; Bai-Ling XU ; Ying GUO
Acta Pharmaceutica Sinica 2013;48(6):860-865
This study is to investigate the mechanism and action characteristics of 6-chloro-3-methyl-4-(2-methyoxycarbonylthiophene-3-sulfonyl)-3, 4-dihydroquinoxa-lin-2-(1 H)-one (XU07011) against HIV-1 replication. XU07011 anti-HIV activity was tested by using VSVG/HIV pseudotype viral system and confirmed by HIV-1 live viruses' infectious assay. Time of addition was used to test HIV-1 reverse transcription process. RNA-dependent DNA polymerase activity and RNase H activity were tested by using enzyme linked immunoabsorbent assay and fluorescence method. Wild type and nine NNRTIs-resistant reverse transcriptase enzymatic models and cell-based pharmacological models were used to evaluate XU07011 bio-characteristics. The results showed that XU07011 inhibited HIV-1 replication with IC50 of (0.057 +/- 0.01) micromol x L(-1) which was comparable to nevirapine [IC50: (0.046 +/- 0.01) micromol x L(-1)]. Mechanism study data indicated that XU07011 blocked HIV-1 reverse transcription process through acting on reverse transcriptase RNA-dependent DNA polymerase with IC 50 of (1.1 +/- 0.3) micromol x L(-1). The compound showed no effect on RNase H activity. XU07011 exhibited better activities comparing with nevirapine on K103N mutated NNRTIs-resistant HIV-1 strains. This study could provide a theoretical basis for novel anti-HIV reagents development.
Anti-HIV Agents
;
chemistry
;
pharmacology
;
Drug Resistance, Viral
;
HEK293 Cells
;
HIV-1
;
physiology
;
Humans
;
Inhibitory Concentration 50
;
Molecular Structure
;
Nevirapine
;
pharmacology
;
Quinoxalines
;
pharmacology
;
RNA-Directed DNA Polymerase
;
metabolism
;
Ribonuclease H
;
metabolism
;
Thiophenes
;
pharmacology
;
Virus Replication
;
drug effects
5.Purification and activity evaluation of methionine synthase.
Ying GUO ; Chao LI ; Zhi-Li ZHANG ; Chao TIAN ; Xiao-Wei WANG ; Jun-Yi LIU
Acta Pharmaceutica Sinica 2012;47(11):1463-1469
Methionine synthase (MS, EC2.1.1.13), a key enzyme in the folate metabolism area catalyzing methyl transfer from N5-methyltetrahydrofolate to homocysteine to give tetrahydrofolate and methionine, takes a core position in folate cycle, one-carbon-unit transfer and sculpture amino acid pathways. Cobalamin-dependent methionine synthase was purified from rat liver. The enzyme was purified 609-fold to near homogeneity by batch chromatography on DE-52, anion-exchange chromatography on Q Sepharose Fast Flow and CHT-I hydroxyapatite column and was identified by SDS-PAGE and Western blotting. The enzyme activity was determined by spectrophotometric assay. In addition, the influencing factor and optimal reaction condition were performed. The steady state kinetic of rat liver methionine synthase was similar to that of other mammalian cobalamin-dependent methionine synthase which employed a Ping-Pong mechanism. The result indicated that cobalamin-dependent methionine synthase purified from rat liver is suitable for screening and studying methionine synthase specific inhibitors.
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
;
isolation & purification
;
metabolism
;
Animals
;
Electrophoresis, Polyacrylamide Gel
;
Folic Acid Antagonists
;
pharmacology
;
Liver
;
chemistry
;
Male
;
Methotrexate
;
pharmacology
;
Quinazolines
;
pharmacology
;
Rats
;
Rats, Wistar
;
Tetrahydrofolates
;
metabolism
;
Thiophenes
;
pharmacology
6.Strontium ranelate promotes osteogenic differentiation of rat bone marrow mesenchymal stem cells by increasing bone morphogenetic protein-7 expression.
Zheng LI ; Yang WANG ; Xiao-na WANG ; Ai-ping LAN ; Wen WU
Journal of Southern Medical University 2011;31(11):1949-1953
OBJECTIVETo explore the role of bone morphogenetic protein-7 (BMP-7) in strontium ranelate (Sr)-induced osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs).
METHODSBMSCs were isolated from 4-week-old rats and cultured in vitro. The third or fourth passages of BMSCs were examined using alkaline phosphatase kit for changes in ALP activity in response to treatment with different concentrations of Sr. Calcium nodules in the induced cells were detected using alizarin red staining, and the cellular BMP-7 expression was detected by Western blotting.
RESULTSWithin the concentration range of 0.1-3.0 mmol/L, Sr dose-dependently increased ALP activity in rat BMSCs. ALP activity reached the highest level after treatment with 3 mmol/L Sr, which also significantly promoted the formation of calcium nodules. Within the range of 0.1-3.0 mmol/L, Sr dose-dependently enhanced the expression of BMP-7, and its peak expression occurred following 3 mmol/L Sr treatment. Noggin (100 ng/ml), an inhibitor of BMP-7, obviously suppressed Sr-induced over-expression of BMP-7 and reduced ALP activity and calcium nodule formation in the BMSCs.
CONCLUSIONSr promotes osteogenic differentiation of rat BMSCs by increasing the expression of BMP-7.
Animals ; Bone Density Conservation Agents ; pharmacology ; Bone Marrow Cells ; cytology ; Bone Morphogenetic Protein 7 ; genetics ; metabolism ; Cell Differentiation ; drug effects ; Cells, Cultured ; Female ; Male ; Mesenchymal Stromal Cells ; cytology ; metabolism ; Organometallic Compounds ; pharmacology ; Osteoblasts ; cytology ; Osteogenesis ; drug effects ; Rats ; Thiophenes ; pharmacology
7.Effect of batimastat on the dynamic changes of matrix metalloproteinases in liver tissue during the development of hepatocellular carcinoma in rats.
Yi GAO ; Zhi ZHANG ; Ze-sheng JIANG ; Shi-gang FANG ; Er-wei SUN ; Jing LIU ; Bao-hua CHEN
Chinese Journal of Hepatology 2003;11(9):570-571
Animals
;
Carcinoma, Hepatocellular
;
enzymology
;
Liver
;
enzymology
;
Liver Neoplasms
;
enzymology
;
Matrix Metalloproteinase 2
;
metabolism
;
Matrix Metalloproteinase 9
;
metabolism
;
Phenylalanine
;
analogs & derivatives
;
pharmacology
;
Protease Inhibitors
;
pharmacology
;
Rats
;
Rats, Wistar
;
Thiophenes
;
pharmacology
8.Design, synthesis and antidepressive activity of duloxetine derivatives.
Yan-ping ZHANG ; Rui XUE ; Xin-hua HE ; Yong-gang MENG ; You-zhi ZHANG ; Bo-hua ZHONG
Acta Pharmaceutica Sinica 2010;45(7):869-873
In this paper, duloxetine was chosen as the lead compound. The pharmacophores with 5-HT(1A) antagonism activity were used to replace the naphthyl of duloxetine. A series of duloxetine derivatives had been designed and synthesized and whose structures were confirmed with elemental analysis, MS and H NMR. All synthesized compounds were tested by tail suspension test and forced swimming test in vivo. The test results revealed that most of the compounds have shown better activity than duloxetine at the same dosage. Some of them are worth to be studied further.
Animals
;
Antidepressive Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
Duloxetine Hydrochloride
;
Hindlimb Suspension
;
Male
;
Mice
;
Mice, Inbred ICR
;
Molecular Structure
;
Serotonin 5-HT1 Receptor Antagonists
;
pharmacology
;
Structure-Activity Relationship
;
Swimming
;
Thiophenes
;
chemical synthesis
;
chemistry
;
pharmacology
9.IκB kinase b Mediating the Downregulation of p53 and p21 by Lipopolysaccharide in Human Papillomavirus 16Cervical Cancer Cells.
Zhi-Hui TAN ; Yu ZHANG ; Yan TIAN ; Wei TAN ; Ying-Hua LI
Chinese Medical Journal 2016;129(22):2703-2707
BACKGROUNDCervical cancer is the second most common cancer of woman in the world, and human papillomavirus (HPV) infection plays an important role in the development of most of the cases. IκB kinase β (IKKβ) is a kinase-mediating nuclear factor kappa B (NF-κB) activation by phosphorylating the inhibitor of NF-κB (IκB) and is related by some diseases caused by virus infection. However, there is little known about the correlation between IKKβ and HPV infection in cervical cancer. This study aimed to investigate the expression of IKKβ protein in cervical cancer tissues and effects of inflammation on HPV positive or negative cervical cancer cells through detecting the expression of IKKβ, IκBα, p53, and p21 proteins after treated with lipopolysaccharide (LPS) to mimic bacterial infection. We also examined the effects of LPS on cervical cancer cells after blocking IKKβ with pharmacological inhibitor.
METHODSThirty-six matched specimens of cervical cancer and adjacent normal tissues were collected and analyzed in the study. The expression of IKKβ in the tissue specimens was determined by immunohistochemical staining. In addition, Western blot was used to detect the expression level changes of IKKβ, IκBα, p53, and p21 after LPS stimulated in the HPV16+ (SiHa) and HPV16- (C33A) cervical cancer cell lines. Furthermore, the effects of IKKβ inhibitor SC-514 on LPS-induced expression change of these proteins were investigated.
RESULTSThe expression of IKKβ was higher in cervical cancer than adjacent normal tissues, and there was no significant difference between tumor differentiation, size, and invasive depth with IKKβ expression. The LPS, which increased the expression level of IKKβ protein but decreased in the IκBα, p53 and p21 proteins, was illustrated in HPV16+ (SiHa) but not in HPV16- (C33A) cells. Moreover, IKKβ inhibitor SC-514 totally reversed the upregulation of IKKβ and downregulation of p53 and p21 by LPS in SiHa cells.
CONCLUSIONSIKKβ may mediate the downregulation of p53 and p21 by LPS in HPV16+ cervical cancer cells.
Cell Line, Tumor ; Down-Regulation ; drug effects ; Female ; Human papillomavirus 16 ; pathogenicity ; Humans ; I-kappa B Kinase ; antagonists & inhibitors ; metabolism ; Lipopolysaccharides ; pharmacology ; Proto-Oncogene Proteins p21(ras) ; metabolism ; Thiophenes ; pharmacology ; Tumor Suppressor Protein p53 ; metabolism ; Uterine Cervical Neoplasms ; metabolism ; virology
10.Case-control study on effect of rivaroxaban on the risk of hidden bleeding after total hip arthroplasty.
Jun LI ; Jue-Hua JING ; Zhan-Jun SHI ; Yun ZHOU
China Journal of Orthopaedics and Traumatology 2014;27(1):34-37
OBJECTIVETo investigate the risk of hidden blood loss about applying rivaroxaban after total hip arthroplasty.
METHODSFrom October 2009 to May 2012,88 patients with femoral head necrosis were treated with primary total hip arthroplasty. All the patients were divided into Rivaroxaban group(44 cases)and control group(44 cases). There were 25 males and 19 females in the Rivaroxaban group, with an average age of (58.48 +/- 15.19) years old; in the control group,24 patients were male and 20 patients were female, with an average age of (61.11 +/- 13.54) years old. The patients in the Rivaroxaban group took Rivaroxaban orally from the first day after operation with a dose of 10 mg each day, and treatment course was 14 days. The patients in the control group took placebo orally at the same time. Dominant blood loss and transfusion were recorded, blood routine examinations were taken before operation and at 3 days after operation. The total blood loss and hidden blood loss were calculated according to the formula.
RESULTSThe mean total blood loss was (1509.56 +/- 325.23) ml and the hidden blood loss was(581.47 +/- 215.01) ml, accounting for (37.88 +/- 10.42)% in the Rivaroxaban group. The mean total blood loss was (1262.30 +/- 397.95) ml and the hidden blood loss was (395.59 +/- 97.33) ml, accounting for (30.62 +/- 0.20)% in the control group. The total blood loss, hidden blood loss and transfusion in the Rivaroxaban group was significantly more than those in control group,b ut there was no significant difference on dominant blood loss between two groups.
CONCLUSIONRivaroxaban increased the overall bleeding risk of total hip arthroplasty, especially hidden bleeding risk, which should be careful used.
Arthroplasty, Replacement, Hip ; adverse effects ; Case-Control Studies ; Female ; Hemorrhage ; etiology ; prevention & control ; Humans ; Male ; Middle Aged ; Morpholines ; pharmacology ; Postoperative Complications ; prevention & control ; Risk ; Rivaroxaban ; Thiophenes ; pharmacology ; Time Factors